By Josh Beckerman

AnaptysBio Inc. shares rose 10% to $27.72 after hours as a second approved indication for a GlaxoSmithKline PLC drug will result in a $20 million milestone payment.

The U.S. Food and Drug Administration approved GSK's Jemperli for the treatment of adult patients with mismatch repair deficient recurrent or advanced solid tumors.

Jemperli was generated by AnaptysBio and subsequently developed by Tesaro Inc., which GSK bought in early 2019.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

August 17, 2021 18:36 ET (22:36 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Gsk
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Gsk